We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bladder Cancer Sniffed Out by Urine Tester

By LabMedica International staff writers
Posted on 22 Jul 2013
Print article
Image: Clarus 500 gas chromatograph (Photo courtesy of PerkinElmer).
Image: Clarus 500 gas chromatograph (Photo courtesy of PerkinElmer).
A device has been developed that can help diagnose the early stages of bladder cancer by analyzing the gas emitted from urine.

The device analyzes the chemicals in the urine odor or headspace and produces a profile readout that shows whether cancer cells are present in the bladder.

Scientists at the University of Liverpool (UK) fabricated a new simple in-house gas chromatography (GC)-sensor device and evaluated it in the diagnosis of bladder cancer based on volatiles. A total of 98 male patients, aged 27 to 91 years, were recruited from urology clinics. There were 24 with bladder cancer and 74 controls, who were patients undergoing investigation for symptoms of bladder outflow obstruction and or hematuria.

The presence of specific volatile organic compounds (VOCs) in the gas emitted from urine samples was analyzed using the in-house fabricated sensor system, called the Odoreader. This consisted of the Clarus 500 gas chromatography oven (PerkinElmer; Waltham, MA, USA) fitted with a commercially available capillary column (Sigma Aldrich; Dorset, UK) which was interfaced to a metal oxide sensor heated to 450 °C that was used as the detector. Additional assistance in evaluating the device was provided by investigators from the University of the West of England (Bristol, UK).

Analysis of the chromatograms showed that 83.3% of bladder cancer samples had a measurable peak in a specific region. In the control samples, peaks in that region of the spectra were predominantly absent. Sensor outputs were analyzed using two different, independent data analysis techniques each of which showed significant discrimination of samples from patients with and without bladder cancer. The identity of the VOCs that contribute to the biomarker profile has yet to be determined. Their characterization may be defined in future work using gas chromatography mass spectrometry techniques and this will provide further insight into bladder cancer induced biochemical changes.

Christopher S. Probert, MD, a senior author of the study said, “Bladder cancer is a disease that, if caught early, can be treated effectively, but unfortunately we do not have any early screening methods other than diagnosis through urine tests at the stage when it starts to become a problem. We have developed a device that can give us a profile of the odor in urine. It reads the gases that chemicals in the urine can give off when the sample is heated.” The study was published on July 8, 2013, in the journal Public Library of Science ONE.

Related Links:

University of Liverpool
PerkinElmer
Sigma Aldrich


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Thrombin Test
i-STAT ACTc Cartridge
New
Multichannel Pipette
CAPPSolo

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.